On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: Population-based data from the Nord-Trøndelag Health Study

Annals of the Rheumatic Diseases

Volumn 75, Issue 5, 2016, Pages 819-824

  Gulati, Agnete Malm ^a,b   Semb, Anne Grete ^c   Rollefstad, Silvia ^c   Romundstad, Pål R ^b   Kavanaugh, Arthur ^d   Gulati, Sasha ^a,b,e   Haugeberg, Glenn ^b,f   Hoff, Mari ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c DIAKONHJEMMET HOSPITAL   (Norway)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Norwegian Centre of Competence in Deep Brain Stimulation for Movement Disorders   (Norway)

^f Hospital of Southern Norway   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RISK ASSESSMENT; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; VERY ELDERLY; ALGORITHM; ARTHRITIS, PSORIATIC; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPLICATION; HEALTH SURVEY; METABOLISM; MIDDLE AGED; NORWAY; PREVALENCE; PROCEDURES; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ARTHRITIS, PSORIATIC; BIOMARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; NORWAY; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 84929593571     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206824     Document Type: Article

References (43)

1. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo-and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005;7:R569-80.
2. Hoff M, Gulati AM, Romundstad PR, et al. Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Trondelag Health Study (HUNT). Ann Rheum Dis 2015;74:60-4.
3. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53:573.
4. Madland TM, Apalset EM, Johannessen AE, et al. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheumatol 2005;32:1918-22.
5. Setty AR, Choi HK. Psoriatic arthritis epidemiology. Curr Rheumatol Rep 2007;9:449-54.
6. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
7. Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013;72:211-16.
8. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131-5.
9. Mok CC, Ko GT, Ho LY, et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 2011;63:195-202.
10. Krokstad S, Langhammer A, Hveem K, et al. Cohort Profile: the HUNT Study, Norway. Int J Epidemiol 2013;42:968-77.
11. Langhammer A, Krokstad S, Romundstad P, et al. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Med Res Methodol 2012;12:143.
12. Dale AC, Vatten LJ, Nilsen TI, et al. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. BMJ 2008;337:a236.
13. Getz L, Sigurdsson JA, Hetlevik I, et al. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. BMJ 2005;331:551.
14. Magnussen EB, Vatten LJ, Lund-Nilsen TI, et al. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ 2007;335:978.
15. Holmen J, Midthjell K, Forsen L, et al. [A health survey in Nord-Trondelag 1984-86. Participation and comparison of attendants and non-attendants]. Tidsskr Nor Laegeforen 1990;110:1973-7.
16. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol 2007;17:643-53.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med 2012;19:403-88.
19. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
20. Han C, Robinson DW Jr., Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72.
21. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology (Oxford) 2008;47:718-23.
22. Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008;47:1286-98.
23. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585-92.
24. Hensrud DD, Klein S. Extreme obesity: a new medical crisis in the United States. Mayo Clin Proc 2006;81:S5-10.
25. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-34.
26. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167:1670-5.
27. Soltani-Arabshahi R, Wong B, Feng BJ, et al. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 2010;146:721-6.
28. Kimhi O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203-9.
29. Rosales Alexander JL, Cantero-Hinojosa J, Salvatierra J, et al. Cardiovascular risk assessment according to a national calibrated score risk index in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Joint Bone Spine 2014;81:164-8.
30. Arts EE, Popa C, Den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 2015;74:668-74.
31. Crowson CS, Matteson EL, Roger VL, et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012;110:420-4.
32. Eder L, Chandran V, Gladman DD. The Framingham risk score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 2014;73:1990-6.
33. Torres T, Sales R, Vasconcelos C, et al. Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. J Dermatol 2013;40:923-6.
34. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16.
35. Robertson J, Peters MJ, McInnes IB, et al. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013;9:513-23.
36. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460-9.
37. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482-7.
38. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:287-93.
39. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005;35:8-17.
40. Sattar N, McCarey DW, Capell H, et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
41. Pahau H, Brown MA, Paul S, et al. Cardiovascular disease is increased prior to onset of rheumatoid arthritis but not osteoarthritis: the population-based Nord-Trondelag health study (HUNT). Arthritis Res Ther 2014;16:R85.
42. Midthjell K, Holmen J, Bjorndal A, et al. Is questionnaire information valid in the study of a chronic disease such as diabetes? The Nord-Trondelag diabetes study. J Epidemiol Community Health 1992;46:537-42.
43. Kehoe R, Wu SY, Leske MC, et al. Comparing self-reported and physician-reported medical history. Am J Epidemiol 1994;139:813-18.